Brief
CEO of Burn Treatment Company MediWound Steps Down
Following a 12-year tenure, Gal Cohen will be replaced by the company’s current chief financial officer Sharon Malka in late May
13:0214.03.19
CEO of Nasdaq-listed biopharmaceutical company MediWound Ltd. Gal Cohen is stepping down from his position after a 12-year tenure, the company announced Tuesday. Cohen will be replaced in late May by the company’s current chief financial officer Sharon Malka.
Retiring MediWound CEO Gal Cohen (left) with appointed CEO Sharon Malka. Photo: PR
Founded in 2001 and based in Yavne, a town central Israel, MediWound develops and manufactures treatments for severe burns and chronic wounds. The company’s flagship product is a pineapple enzyme-based treatment used for the removal of dead tissue from burn wounds.
Retiring MediWound CEO Gal Cohen (left) with appointed CEO Sharon Malka. Photo: PR
